Market Overview

Ariad Pharmaceuticals Cash Acquisition by Takeda Pharmaceuticals Could a Second Buyer Surface

Share:


NEW YORK, NY / ACCESSWIRE / January 10, 2017 /
Traders News Source, an equity research firm specializing in small and micro-cap securities, is looking at recent events Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), a biotechnology company focused on precision therapies for patients with rare cancers. The company announced on January 9, 2017 that Takeda Pharmaceutical offered $24 in cash for 100% of the Company.

Have investors received all the gains they should expect from Ariad, or
could an alternative buyer surface? Read our Full Report.

(Copy and paste to your browser may be required - http://bit.ly/2jrDpua-ARIA-Report)

Prior to this announcement, ARIA posted earnings for the third quarter of 2016 on November 7, 2016. Both revenues and EPS beat consensus expectations. ARIA stock has rocketed over 343% over the last year. Should shareholders just accept Takeda's offer and move on from future deal risk? Or could another unexpected buyer enter with a higher price?

Get the Ariad Q3 financial and stock price
analysis in our Full Report.

(Copy and paste to your browser may be required - http://bit.ly/2jrDpua-ARIA-Report)

DISCLOSURE

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content, generally in the form of press releases, articles, and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Stuart Quint, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments, reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email between 09:30 EST to 16:00 EST from Monday through Friday at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source

View Comments and Join the Discussion!